Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Chennai, Jan. 26 -- Highlights: ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease ...

Lactated Ringers Injection Market to reach USD 2.9 Bn by 2036, driven by rising hospital admissions, increasing surgical ...

Nurse Practitioner Brings First Health and Wellness Franchise to the Community Hydrate IV Bar proudly announces the grand ...

A Nashville judge has ordered the Tennessee Department of Correction to allow reporters to witness the full execution of ...

New nanomaterial passes the blood-brain barrier to reduce damaging inflammation after the most common form of stroke. When ...

Autopsy reveals difficulty with IV insertions during executions in Arizona, raising concerns about medical practices for ...

The State of Alabama has settled a lawsuit with Aurora IV and Wellness, a Cullman-based IV infusion clinic, and its owners, Amanda and Chris Medders. According to a press release […] ...